SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: January 26, 2005
(Date of earliest event reported)
VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-18105 11-2871434
--------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
180 Linden Avenue, Westbury, New York 11590
------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code (516) 997-4600
--------------
Not applicable
--------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
[ ] Pre-commencement communications pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)
INFORMATION TO BE INCLUDED IN THE REPORT
The information in this Form 8-K Current Report and the exhibit attached
hereto is furnished and shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing of the Registrant under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 8.01 Other Events
The Company has been informed that at the American College of Cardiology's
session entitled "Late-Breaking Clinical Trials: Mechanisms and New Therapeutic
Approaches", to be held on March 8, 2005 at 4:15 p.m. in Orlando, Florida, a
presentation will be made with respect to the Company's PEECH Clinical Study.
The presentation is entitled "Prospective Evaluation of EECP in Congestive Heart
Failure."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
VASOMEDICAL, INC.
/s/Thomas W. Fry
-------------------------
Thomas W. Fry
Chief Financial Officer
(Principal Financial and Accounting
Officer)
Dated: January 26, 2005